Carl C Crodel
Overview
Explore the profile of Carl C Crodel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jilg S, Schwaab J, Sockel K, Crodel C, Brueckl V, Stegelmann F, et al.
Ann Hematol
. 2024 Jul;
103(10):4065-4077.
PMID: 39073589
Recurrent problems of patients with myelofibrosis (MF) are cytopenias, debiliating disease-related symptoms and splenomegaly. Whereas the latter are usually addressed by the JAK1/2 inhibitors ruxolitinib and fedratinib, cytopenias often remain...
2.
Zaninetti C, Vater L, Kaderali L, Crodel C, Schnoder T, Fuhrmann J, et al.
Leukemia
. 2024 Jul;
38(9):2051-2058.
PMID: 39020061
No abstract available.
3.
Hinze A, Rinke J, Crodel C, Mobius S, Schafer V, Heidel F, et al.
Br J Haematol
. 2023 May;
202(2):308-317.
PMID: 37139709
Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS)...
4.
Schmidt A, Bernhardt C, Burkle D, Fries S, Hannig C, Jentsch-Ullrich K, et al.
J Cancer Res Clin Oncol
. 2023 Mar;
149(10):7197-7206.
PMID: 36884118
Purpose: The WHO 2016 re-classification of myeloproliferative neoplasms resulted in a separation of essential thrombocythemia (ET) from the pre-fibrotic and fibrotic (overt) phases of primary myelofibrosis (MF). This study reports...
5.
Stegelmann F, Teichmann L, Heidel F, Crodel C, Ernst T, Kreil S, et al.
Leukemia
. 2023 Feb;
37(4):924-928.
PMID: 36828867
No abstract available.
6.
Ernst P, Schnoder T, Huber N, Perner F, Jayavelu A, Eifert T, et al.
Leukemia
. 2022 Jun;
36(7):1843-1849.
PMID: 35654819
Mutations of the JAK2 gene are frequent aberrations in the aging hematopoietic system and in myeloid neoplasms. While JAK-inhibitors efficiently reduce hyperinflammation induced by the constitutively active mutated JAK2 kinase,...
7.
Frietsch J, Miethke J, Linke P, Crodel C, Schnetzke U, Scholl S, et al.
Bone Marrow Transplant
. 2022 May;
57(7):1164-1170.
PMID: 35538141
Conditioning with treosulfan and fludarabine (Treo/Flu) has been proven to be feasible and efficient in several types of malignancies before allogeneic hematopoietic stem cell transplantation (allo-HSCT). Given its favorable reduced...
8.
Crodel C, Jentsch-Ullrich K, Reiser M, Jacobasch L, Sauer A, Tesch H, et al.
J Cancer Res Clin Oncol
. 2021 Nov;
148(10):2693-2705.
PMID: 34807311
Purpose: Patients with polycythemia vera (PV) show an elevated incidence of thromboembolic complications and decreased survival when compared to age-matched healthy individuals. Hypercellularity as indicated by elevated hematocrit, pathophysiological changes...
9.
Crodel C, Jentsch-Ullrich K, Koschmieder S, Kampfe D, Griesshammer M, Dohner K, et al.
Leukemia
. 2020 Jul;
34(11):3106.
PMID: 32651539
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
10.
Crodel C, Jentsch-Ullrich K, Koschmieder S, Kampfe D, Griesshammer M, Dohner K, et al.
Leukemia
. 2020 Jun;
34(7):1949-1953.
PMID: 32474573
No abstract available.